|Publication number||US8007429 B2|
|Application number||US 12/166,664|
|Publication date||Aug 30, 2011|
|Filing date||Jul 2, 2008|
|Priority date||Jul 5, 2007|
|Also published as||CN101677851A, CN101677851B, EP2170221A2, EP2170221A4, US20090012351, WO2009006574A2, WO2009006574A3|
|Publication number||12166664, 166664, US 8007429 B2, US 8007429B2, US-B2-8007429, US8007429 B2, US8007429B2|
|Inventors||David W. Anderson, Gerald W. Timm|
|Original Assignee||Gt Urological, Llc|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (20), Non-Patent Citations (2), Referenced by (4), Classifications (13), Legal Events (2)|
|External Links: USPTO, USPTO Assignment, Espacenet|
The present application claims the benefit of U.S. Provisional Patent Application Ser. No. 60/958,157 entitled “TAPE MECHANICAL OCCLUSIVE DEVICE” filed on Jul. 5, 2007, which is herewith incorporated by reference in its entirety.
This invention was made with government support under SBIR Grant Number 1 R43 DK076397 01A1 awarded by the National Institutes of Health. The government has certain rights in the invention.
This document generally relates to an occlusive device for occluding fluid conveying vessels in the body and particularly, but not by way of limitation, to a urethral occlusive device for preventing urinary incontinence.
Vessel occlusive devices are well known and commonly referred to as “artificial Sphincters”. They are installed within the body to aid or replace the natural sphincter of the body. For example, men become urinary incontinent following surgeries to remove cancerous prostates. Women are often rendered incontinent due to the pelvic trauma caused during childbirth and due to a laxity of the pelvic muscles occurring due to aging. To a lesser degree, men and women may be rendered incontinent due to trauma, infection and birth defects. Urethral occlusive devices can be used to restore urinary continence to patients with urinary control problems caused by various neurological diseases, surgical procedures, spinal cord injury, etc. Other occlusive devices include those used for contracting the bowel to prevent fecal leakage, for contracting the esophagus to prevent gastro-esophageal reflux, or those used in the area of gastric banding for restricting the stomach in treatment for obesity, and occlusion of the seminal vesicles or fallopian tube to control male and/or female fertility, of which there are needs that exist for commercial devices that can be used in such applications.
In particular, devices utilizing hydraulic sphincters or cuffs described in U.S. Pat. Nos. 3,863,622; 4,222,377, 4,412,530 and 4,878,889, have been used to provide urethral occlusion. To use these types of devices, the patient squeezes a control pump, which transfers fluid from a cuff to a pressure regulating balloon. The balloon forces the fluid through a fluid restrictor and back into the cuff to reestablish an occlusive urethral pressure within 3-5 minutes. These urethral occlusive devices are complicated to implant. One problem with hydraulic sphincters or cuffs is that they often do not apply uniform pressure on the urethra. As the cuff or sphincter is inflated, it folds or changes its shape, often in a non-uniform manner, thereby exerting uneven occlusive force on the urethra. This can result in urinary leakage, urethral erosion, or the urethra tissue being worn away after extensive use.
In other examples, the American Medical Systems, Inc. AUS 800 is a commercially available, totally implantable artificial urinary sphincter. The complexity of its implantation is due to the requirement to intra-operatively fill and assemble its three components. The AUS 800 often fails due to wear in its componentry which leads to fluid leakage. Urethral atrophy and erosion sometimes occur and are suspected to be due to the crenate shape of its occlusive cuff. Post-operative infection requiring explantation of the device also is a frequent complication.
U.S. Pat. Nos. 5,704,893 and 6,074,341 discuss other types of urethral occlusive devices, which are entirely implantable artificial urinary sphincters. These artificial urinary sphincters are one-piece devices that do not require saline filling or intra-operative assembly, but where depression of a deactivation plunger, for example through the scrotal skin, causes a urethral occlusive sheath to expand and remove occlusive pressure from the urethra to allow normal urination. Depression of an activation button allows the occlusive sheath to contract and reapply urethral pressure to prevent urethral leakage. While such devices provided significant improvement in vessel occlusion, implantation in humans was impeded by growth of tough, fibrous tissue around the device, due to the natural defenses of the human body, which over time prevented expansion of the occlusive sheath.
For these and other reasons, there is a need to provide a practical and effective vessel occlusive device for aiding or replacing the natural sphincter of the body.
Generally, vessel occlusive devices are described and methods for occluding a vessel or vessels that convey fluid in humans and animals are described. As one particular example, the vessel occlusive devices and methods described herein involve occluding a urethra by implanting a device into a human body for providing an incontinent patient protection against urine leakage and for providing control over the patient's voiding function.
A vessel occlusive device generally includes an occlusive member and a control mechanism for actuating the occlusive member into occluding and non-occluding positions. The occlusive member includes a pliable region configured to apply a constant force on a targeted vessel when the occlusive member is actuated in the occluding position. The occlusive member can also be configured to passively elute a solution through the occlusive member.
In accordance with the inventive principles herein, one embodiment of an apparatus for occluding a fluid conveying vessel in a body includes an occlusive member having a conduit region proximately disposed toward a proximate end and a pliable region proximately disposed toward a distal end. The occlusive member is actuatable to an occluding position and is actuatable to a non-occluding position, where an occlusive force is respectively transmitted to and released from the occlusive member. The pliable region is configured to at least partially encircle the vessel, and is configured to exert an occluding pressure on the vessel when the occlusive force is transmitted through the conduit region. A control mechanism is connected to the conduit region of the occlusive member. The control mechanism is configured to actuate the occlusive member into the occluding position and actuate the occlusive member into the non-occluding position.
In one embodiment, the occlusive member is constructed and arranged with an inner extrusion covered by an outer extrusion. The inner and outer extrusions are porous, where the outer extrusion is less porous than the inner extrusion.
In another embodiment, the occlusive member includes at least one suture lumen extending from the proximate end to the distal end, and a traction suture connected to the control mechanism and extending through the suture lumen. The control mechanism is configured to actuate the traction suture so that the occlusive member is in the occluding position and configured to actuate the traction suture so that the occlusive member is in the non-occluding position.
In another embodiment, the conduit region has a higher stiffness than the pliable region.
In one embodiment, a boot is employed to cover the control mechanism. In some examples, the boot includes a septum configured for introducing at least one fluid into the control mechanism and the occlusive member. In some examples, the fluid to be introduced includes at least one of a solution to replace air space within the control mechanism and occlusive member and a solution to provide a therapeutic effect.
In accordance with the inventive principles herein, one embodiment of a method for controlling fluid flow in a fluid conveying body vessel includes implanting a vessel occlusive device inside the body of a subject in need of controlled fluid flow through a fluid conveying vessel. The step of implanting includes surrounding at least a portion of the fluid conveying vessel, actuating the vessel occlusive device into a biased occluding position, thereby applying an occlusive force to occlude the fluid conveying vessel. The occlusive force applied to the fluid conveying vessel is released when fluid flow is to be allowed through the fluid conveying vessel. The step of releasing occlusive force includes actuating the vessel occlusive device away from the biased occluding position to a non-occluding position. The vessel occlusive device is then reactuated into the biased occlusive position when fluid flow is no longer to be allowed.
In one embodiment, a method for controlling fluid flow in a fluid conveying body vessel includes applying a constant force on the fluid conveying vessel during at least one of the implanting and the reactuating steps.
In another embodiment, a method for controlling fluid flow in a fluid conveying body vessel includes passively eluting at least one solution from the vessel occlusive device into the body to provide a therapeutic effect.
In yet another embodiment, the step of releasing the occlusive force applied to the fluid conveying vessel includes one of holding the vessel occlusive device in the occluding position and locking the vessel occlusive device in the occluding position.
The drawings, which are not necessarily drawn to scale, illustrate generally, by way of example, but not by way of limitation, various embodiments discussed in the present document.
In the following detailed description, reference is made to the accompanying drawings which form a part hereof, and in which is shown, by way of illustration, specific embodiments in which inventive concepts may be practiced. These embodiments are described in sufficient detail to enable those skilled in the art to practice the invention, and it is to be understood that the embodiments may be combined or used separately, or that other embodiments may be utilized and that structural and procedural changes may be made without departing from the spirit and scope of the inventive concepts. The following detailed description provides examples, and the scope of the present invention is defined by the claims to be added and their equivalents.
It should be noted that references to “an,” “one,” or “various” embodiments in this disclosure are not necessarily to the same embodiment, and such references contemplate more than one embodiment.
The terms “above,” “on,” “under,” “top,” “bottom,” “up,” “down,” “horizontal,” and “vertical” and the like used herein are in reference to the relative positions of the vessel occlusive device, and its constituent parts, in use when oriented as in
In this document, the terms “occlude,” “occluding,” “occlusive” or “occlusion” respectively mean partially or completely occlude, partially or completely occluding, partially or completely occlusive, or partial or complete occlusion.
In this document, the terms “encircle,” “surround” or “enclose” respectively mean partially or completely encircle, surround or enclose.
This document generally discusses, among other things, vessel occlusive devices and methods for occluding a vessel or vessels that convey fluid in humans and animals. As one particular example, the vessel occlusive devices and methods herein discuss applications that involve occluding a urethra by implanting a one-piece artificial device in a human body for providing an incontinent patient protection against urine leakage and for providing control over the patient's voiding function. However, it is to be understood that the present devices and methods may be employed in other areas, including, but not being limited to, fecal incontinence, gastro-esophageal reflux disease, and gastric banding for weight loss, bile duct flow control, male and/or female fertility control through reversible occlusion of the seminal vesicles or fallopian tube, or to provide general occlusion or support of body vessels for other purposes. Generally, it will be appreciated that the discussion below can apply to various vessels and/or body parts that can convey fluid and may have a need to be restricted or occluded by an occlusive device. It is also to be understood that the occlusive devices described herein may include multiple pieces or components operatively connected to each other, and that they may be either partially or entirely implantable in the body of humans or animals.
Vessel occlusive devices as described herein generally include an occlusive member and a control mechanism for actuating the occlusive member into occluding and non-occluding positions. The occlusive member is configured to apply a constant force on a targeted vessel when the occlusive member is actuated in the occluding position. The occlusive member can also be configured to passively elute a solution through the occlusive member.
Methods for controlling fluid flow in a fluid conveying body vessel include implanting a vessel occlusive device inside the body of a subject in need. The step of implanting includes surrounding at least a portion of the fluid conveying vessel and actuating the vessel occlusive device to apply an occlusive force and occlude the fluid conveying vessel. The occlusive force is released when fluid flow is to be allowed through the fluid conveying vessel. The step of releasing occlusive force includes actuating the vessel occlusive device to a non-occluding position. The vessel occlusive device is then reactuated into the occlusive position when fluid flow is no longer to be allowed. In one embodiment, a constant force can be applied on the fluid conveying vessel during at least one of the implanting and the reactuating steps. In another embodiment, at least one solution is passively eluted from the vessel occlusive device into the body to provide a therapeutic effect.
As illustrated in
In one embodiment, the vessel occlusive devices 10, 110 and at least its occlusive member 14, 114, are typically shipped with the pliable region 18, 118 in an open configuration (see for example
In one embodiment, a clip-band mechanism can be used for attaching the distal end 26, 126 to the attachment portion 32, 132. The clip-band mechanism includes a clip 22, 122 formed on the distal end 26, 126 of the occlusive member 14, 114, and a band 28, 128 wrapping around the attachment portion 32, 132, where the clip 22, 122 is engageable with the band 28, 128. As shown in
In one embodiment, the band 28, 128 includes a main body 46, 146 and a wrapping member 48, 148 that can wrap around the attachment portion 32, 132. In one embodiment, when the band 28, 128 is wrapping around the attachment portion 32, 132, the main body 46, 146 is located above the attachment portion 32, 132. A transverse aperture 40, 140 extends through a first side surface 42, 142 of the main body 46, 146 and a second side surface 44, 144 for receiving the second prong (e.g. 130) of the clip 22, 122.
The distal end 26, 126 includes an end cap 24, 124 that can engage the clip 22, 122 (e.g. first prong 134). In one embodiment, the first prong 134 of the 122 clip is inserted into an injection or transfer molded silicone end cap 124. An example of a suitable silicone is a silicone manufactured by Nusil, Inc. of Carpenteria, Calif.
The clip 22, 122 is configured to clip on the band 28, 128 with the second prong 30, 130 being inserted and extended through the aperture 40, 140, so that the distal end 26, 126 is clipped on and against the wrapping member 48 and 148. In such a configuration, the clip 22, 122 is engaged with and can be locked onto the band 28, 128 so that the pliable region 18, 118 is held in a generally circular position and encircles the vessel 12 in a manner as shown in
The clip 22, 122 may be manufactured from 316L stainless steel, 6A14Veli titanium, or plastics by machining, metal stamping or plastic or metal injection molding processes. As one example of a suitable material, a poly ether ether ketone (PEEK) such as manufactured by Invibio, Inc. of Greenville, S.C. can be employed.
In one embodiment, as shown in
With reference to
The inner extrusion 160 also can be made of expanded polytetrafluoroethylene (ePTFE), and can be manufactured having a porosity in a range of approximately 80-100 microns, which insures that the extrusion 160 compresses greatly when an axial load is applied. The extrusions 150, 160 can be manufactured by several companies, such as International Polymer Engineering, Inc. of Tempe, Ariz.
In one embodiment, the inner extrusion 160 includes a lumen 162 generally located in the center of the extrusion 160 and at least one suture lumen 156 generally located peripherally of the lumen 162. In one embodiment, both the lumen 162 and the suture lumen 156 extend through the entire length of the occlusive member 114. It will be appreciated, however, that the central lumen 162 may not extend through the entire length of the occlusive member 114. It is to be understood that the positioning of the lumens can be varied, depending on the specific shape of the occlusive member 114. It is also to be understood that the number of lumens can vary as desired and/or necessary, depending on for example the occlusive force to be transmitted through the suture lumens and the stiffening quality needed for a conduit region of the occlusive member 114 (discussed below).
The occlusive member 114 further includes traction sutures 154. In one embodiment, the traction sutures are affixed to the end cap 124 and extend through lumens 156 within the inner extrusion 160. Force or tension applied by the control mechanism 116 can be transmitted to the pliable region 118 through the suture 154 to put the pliable region 118 into an occluding position (
As further shown, the occlusive member 14, 114 includes a conduit region 20, 120 that connects the pliable region 18, 118 to the control mechanism 16, 116. The conduit region 20, 120 of the occlusive member 14, 114 in some embodiments is more rigid or stiff than the pliable region 18, 118. For example, the conduit region 20, 120 is made stiffer than the pliable region 18, 118 by feeding a closely-wound wire coil 158 through a portion of the lumen 162 of the inner extrusion 160 to prevent collapse. By way of example only, the coil 158 can be wound using standard coil winding techniques and may be manufactured from materials as a nickel-cobalt alloy, such as the known 316 stainless steel or MP35NŽ. It will be appreciated that the conduit region 20, 120 may be made with rigid, stiff properties using a variety of implementations and techniques and is not meant to be limited to the specific structure shown. As one example only, a central lumen and coil may not be employed, but where portions of the extrusions 150, 160 which correspond to the conduit region 20, 120 may be constructed and formed of a material so as to provide the needed rigidity relative to the pliable region 18, 118.
With reference to
With further reference to
With reference to FIGS. 1 and 6A-6D, the control mechanism 16 is attached to the occlusive member 14. Traction sutures 54 extend from the occlusive member 14 and are attached to a cable and pulley system for positioning the device 10 into the occluding and non-occluding positions. As shown, pulley 68 is situated and free to rotate within the control mechanism 16. The traction sutures 54 are connected to the pulley 68.
The pulley 68 may be machined or injection molded from a host of materials including, but not limited to, ultra high molecular weight polyethylene (UHMWPE), poly ether-ether ketone (PEEK), titanium 6A14Veli or 316 stainless steel.
A biasing member of constant force is disposed within the center of the pulley 68. As one example, the biasing member is a coiled spring 70 disposed within the center of the pulley 68. As shown, the spring 70 in one embodiment is disposed within a circular pocket of the pulley 68 (see for example
In one embodiment, the coiled spring 70 is biased to apply an initial constant force or tension on the attached traction sutures 54 (see
Exemplary embodiments are described and shown below which transmit force to the occlusive member and remove force therefrom. In a first exemplary embodiment shown in
With further reference to
It is to be understood that the ratio of the two pulley diameters may be varied to maximize the degree of counter-rotation of the large pulley 68 and to minimize the axial movement of the plunger 72. Smaller plunger movements can ease the manual operation by the user. As some examples only, axial movements can be maintained in the range of approximately 0.10″ to 0.50″ inches. For example, initial rotation of the larger pulley 68 may be intended to provide the greatest degree of vessel 12 compression possible, for example a male or female urethra. In such a case, the larger pulley 68 can be initially rotated or biased into the compression or occluding position to provide approximately 2.5 cm to 4.0 cm linear take up of the traction sutures 54. To account for such initial linear take up of the traction sutures 54, the pulley, cable, and plunger structure can be suitably modified so that a suitable counter rotation can be achieved to release tension on the traction sutures 54.
The user has the option of depressing and holding the plunger 72 in its depressed state while urinating or depressing the plunger 72 until it locks into a fully depressed condition as shown in
In a second exemplary embodiment for transmitting force to and from the occlusive member,
In yet another embodiment for transmitting force to and from the occlusive member,
As shown, when the plunger 172 is depressed to its full extent, a pin 190 disposed on the plunger 172 engages a detent of the lever 182, which locks the plunger 72 and prevents it from returning to its original extended position. The lever 182 can be biased by a spring 192. In one embodiment, the spring 192 is disposed between the lever 182 and a generally flexible silicone rubber cover or boot 164 substantially surrounding the control mechanism 116. As the plunger 172 is depressed, a plunger dome 194 of the flexible silicone boot 164 deforms with the force applied to it, but can also return to its original shape when the force is removed. In the configuration shown, the occlusive member can be locked in a state which does not compress the vessel 112 and can be released from a locked position to return compression to the vessel 112. The resilient plunger dome 194 can help prevent tissue from forming around the device when it is implanted, and can help prevent movement of the plunger 172 from being restricted.
When a user desires to return to a continent state with the vessel compressed, the lever 182 is depressed so that the pin 190 of the plunger 172 can disengage from the detent of the lever 182. Such an action allows the plunger 172 to return to an extended position, for example as a result of the bias of the spring 170.
With reference to
In one embodiment, the control mechanism 216 includes a pulley 268 operatively connected to an electric motor 295. The electric motor 295 is operatively connected to a micro-processor based control 297 having a power supply 296. A separate vessel pressure sensing element 298 is operatively connected to the micro-processor based control 297, for instance through a wire 294. A pressure sensing element 299, such as for example the abdomen, is operatively connected to the micro-processor based control 297, for instance through a wire 293. In the embodiment shown, the electric motor 295 can turn the pulley 268, which in turn takes up and applies a load to a traction suture 254, to compress or constrict the occlusive member 214 to thereby occlude the vessel 212.
In the example of urethral occlusion only, the pulley 268 in its resting state is biased so that the occlusive member 214 can apply approximately 0 to 20 cm H20 pressure to the urethra. Such a pressure range has been known to be adequate to prevent urinary leakage during normal, less stressful activities. It will be appreciated that lesser and higher pressures may be employed depending on the particular user. Urethral pressure can be continuously or intermittently monitored by the pressure sensing element 298. The pressure sending element 298 can be situated between the occlusive member 214 and the outer surface of the vessel 212 or urethra in this case. Abdominal or bladder pressure is monitored continuously or intermittently by the pressure sensor 299 which is implanted, for example within any of the abdominal cavity, the abdominal wall, the bladder, or the bladder wall.
As bladder filling occurs, bladder pressure increases for example within the range of approximately 20-60 cm H20. In one example of operation, the pressure sensor 299 senses this pressure increase, and signals the micro-processor based control 297 to turn the motor 295 on, and cause the pulley 268 to rotate and increase tension on the tracking suture 254 to affect a rise in urethral pressure. When the pressure sensing element 298 detects that urethral pressure is 60-80 cm H20, the motor 295 is turned off and the pulley 268 can be held in position to prevent any further pressure increase or decrease. Once the abdominal/bladder pressure reduces to 20 cm H20 or less, the pressure sensor 299 signals the micro-processor based control 297 to allow the motor 295 to reverse direction and reduce tension on the traction suture 254 until urethral pressures between 0 and 20 cm H20 are achieved. Such a configuration can provide a vessel occlusive device with automatic control.
Stressful events such as coughing, sneezing, laughing, etc. can often cause abdominal/bladder pressures spikes in excess of 60 cm H20. Pressure rise times of about 35 milliseconds (msec) and elevated pressure durations of approximately 100 msec have been recorded for such events. Sensing such pressure levels, the micro-processor based control 297 in operation can cause the motor 295 to turn on and can rotate the pulley 268 to affect a rise in urethral pressure. For example, the urethral pressure can rise as high as approximately 120 cm H20. When abdominal/bladder pressure declines to approximately 20 cm H20 or less, the micro-processor based control 297 allows the motor 295 to reverse direction and reduce tension on the traction sutures 254 until urethral pressures between approximately 0 and 20 cm H20 are achieved.
When the user wishes to void urine, the micro-processor based control can include a switch 291 that can be manually activated through the skin. It will be appreciated that a variety of implementations of electromechanical levers, buttons, and the like may be employed on or operatively connected to the micro-processor based control 297. It further will be appreciated that the switch 291 may be a wired or wireless electrical switch. By activating the switch 291, the pulley 268 for example can be caused to free-wheel, thereby reducing tension on the traction suture 254 until approximately between 0 and 20 cm H20 urethral pressure is achieved. The user can then void urine through the unobstructed urethra (e.g. vessel 212). The user may then be required to manually activate the switch again to return the device 210 to its resting or occlusive mode. In other embodiments, the device can be suitably programmed to automatically return to its resting or occlusive mode, such as within 3-5 minutes.
As described, any of the vessel occlusive devices can be implanted in both males and females. For example, a vessel occlusive device 10 in
For females, any of the occlusive devices can be implanted through a transvaginal or abdominal incision and employing similar deactivation/activation procedures as with males. Any of the occlusive members can be disposed to encircle the bladder neck or mid-urethra. Any of the control mechanisms can be miniaturized for female implantation in the labia or abdominal skin, where it could be operated by manual depression of a plunger such as through the labial or abdominal tissue.
Another benefit of the vessel occlusive devices described herein is that fluid loss will not render the device inoperative. For example, other artificial urinary sphincter concepts are hydraulic (e.g. bias applied to the urethra through a pressurized balloon). When a leak develops, devices employing such concepts become inoperative since the balloon is no longer pressurized. The inventive concepts described herein may allow fluid to leave an occlusive device without affecting its function.
With reference to
The vessel occlusive device 110 may be filled with therapeutic solutions using for example a syringe 400. The therapeutic solution can be delivered to surrounding tissues over time. As shown, the control mechanism 116 in one embodiment is encapsulated by a silicone rubber boot 164 which offers an integral rubber needle puncture septum 166. As a solution(s) fills the control mechanism 116, it can wick towards and through the porous structure of the occlusive member 114. When droplets of solution appear on the surface of the pliable region 118 of the occlusive member 114, the device 110 has been fully filled and the needle is withdrawn from the septum 166. Once the device is implanted, the solutions can continue to elute passively from the occlusive member 114 into the surrounding tissue to provide their therapeutic effect. It will be appreciated that solutions may also be refilled as needed, so that the device can provide for extended and/or indefinite elution. It also will be appreciated that solutions can be infused into the device 110, if required due to infection or tissue capsule growth, by accessing the septum 166 with a needle through the user's skin and so that the device need not be removed.
In one embodiment, the occlusive member 114 as described has a micro-porous construction intended to minimize tissue in-growth, yet allow drug to elute from its surface. These drug solutions may be selected to prevent post-operative infections and/or minimize pseudo-capsular formation which may inhibit the contraction or expansion of the occlusive member 114.
It is to be understood that the above detailed description is intended to be illustrative, and not restrictive. Other embodiments, including any process of using a thermoplastic medium for imprinting a print and in turn making a personalized ornamental article, will be apparent to those of skill in the art upon reading and understanding the above description. The scope of the invention should, therefore, be determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US3863622||Jan 9, 1973||Feb 4, 1975||Robert Enno Buuck||Incontinence system and methods of implanting and using same|
|US3903894||Jul 26, 1974||Sep 9, 1975||Isaac Michael Rosen||Implantable clamp|
|US4118805||Feb 28, 1977||Oct 10, 1978||Codman & Shurtleff, Inc.||Artificial sphincter|
|US4222377||Jun 27, 1977||Sep 16, 1980||American Medical Systems, Inc.||Pressure regulated artificial sphincter systems|
|US4412530||Sep 21, 1981||Nov 1, 1983||American Medical Systems, Inc.||Dual-mode valve pressure regulating system|
|US4878889||Jun 24, 1988||Nov 7, 1989||American Medical Systems, Inc.||Artificial sphincter device|
|US4938760||Mar 29, 1989||Jul 3, 1990||American Medical Systems, Inc.||Female suspension procedure|
|US4994020||Jul 21, 1989||Feb 19, 1991||American Medical Systems, Inc.||Implantable artificial sphincter system|
|US5509888||Jul 26, 1994||Apr 23, 1996||Conceptek Corporation||Controller valve device and method|
|US5518504||Dec 28, 1993||May 21, 1996||American Medical Systems, Inc.||Implantable sphincter system utilizing lifting means|
|US5704893||Nov 12, 1996||Jan 6, 1998||Dacomed Corportion||Vessel occlusive apparatus and method|
|US5888188||Jun 7, 1996||Mar 30, 1999||Fundacao E. J. Zerbini||Mechanical sphincter for controlling urinary incontinence|
|US6074341||Jun 9, 1998||Jun 13, 2000||Timm Medical Technologies, Inc.||Vessel occlusive apparatus and method|
|US6117067||Aug 11, 1998||Sep 12, 2000||Gil-Vernet; Josema||Device for the height-adjustable fixing and support of internal anatomical organs|
|US6463935||Feb 10, 2000||Oct 15, 2002||Obtech Medical Ag||Controlled heartburn and reflux disease treatment|
|US6709385||Feb 8, 2001||Mar 23, 2004||Obtech Medical Ag||Urinary incontinence treatment apparatus|
|US7060080||Sep 3, 2003||Jun 13, 2006||Endoart S.A.||Closure system for surgical ring|
|US20020111530||Feb 15, 2001||Aug 15, 2002||Ramesh Bakane||Artificial urinary sphincter|
|US20050251182||Sep 3, 2003||Nov 10, 2005||Bachmann Michel A||Surgical ring featuring a reversiblediameter remote control system|
|US20060264697||May 16, 2006||Nov 23, 2006||Gt Urological, Llc.||Drug elution for implantable incontinence devices|
|1||International Search Report of PCT/US2008/069155, dated Jan. 30, 2009.|
|2||Written Opinion of the International Searching Authority of PCT/US2008/069155, dated Jan. 30, 2009.|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US8753363||Jan 18, 2012||Jun 17, 2014||Gt Urological, Llc||Vessel occlusive device and method of occluding a vessel|
|US8758218 *||Apr 23, 2012||Jun 24, 2014||Coloplast A/S||Method of treating incontinence and treatment device including non-porous cuff and extending members|
|WO2013158586A1 *||Apr 16, 2013||Oct 24, 2013||Gt Urological, Llc||Hydraulic urethral occlusive device|
|WO2015021146A1 *||Aug 6, 2014||Feb 12, 2015||Gt Urological, Llc||Hydraulic urethral occlusive device|
|Cooperative Classification||A61F2/0027, A61B17/1327, A61B2017/00805, A61M39/0208, A61B17/1322, A61B2017/00398, A61B2017/0042, A61B2017/00893|
|European Classification||A61B17/132G, A61M39/02B, A61F2/00B4B|
|Jul 2, 2008||AS||Assignment|
Owner name: GT UROLOGICAL, LLC, MINNESOTA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ANDERSON, DAVID W.;TIMM, GERLAD W.;REEL/FRAME:021190/0916
Effective date: 20080701
|Jan 15, 2015||FPAY||Fee payment|
Year of fee payment: 4